Business

Announcement on Voluntary Disclosure of the Initiation of Phase 1 Clinical Trial and Completion of 1st Subject Enrollment for Inhalable Tuberculosis Vaccine (Type 5 Adenovirus Vector) in Indonesia

Announcement on Voluntary Disclosure of the Initiation of Phase 1 Clinical Trial and Completion of 1st Subject Enrollment for Inhalable Tuberculosis Vaccine (Type 5 Adenovirus Vector) in Indonesia

articleCansino Biologics, Inc. Class ANovember 13, 20254/news/announcement-on-voluntary-disclosure-of-the-initiation-of-phase-1-clinical-trial-and-completion-of-1st-subject-enrollment-for-inhalable-tuberculosis-vaccine-type-5-adenovirus-vector-in-indonesia
Announcement on Voluntary Disclosure of the Initiation of Phase 1 Clinical Trial and Completion of 1st Subject Enrollment for Inhalable Tuberculosis Vaccine (Type 5 Adenovirus Vector) in Indonesia

About this update from Cansino Biologics, Inc. Class A

Announcement on Voluntary Disclosure of the Initiation of Phase 1 Clinical Trial and Completion of 1st Subject Enrollment for Inhalable Tuberculosis Vaccine (Type 5 Adenovirus Vector) in IndonesiaThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Cansino Biologics, Inc. Class A